Experience from Asian Centers in a Named-Patient-use Program for Afatinib in Patients with Advanced Non-Small-cell Lung Cancer Who Had Progressed Following Prior Therapies, Including Patients with Uncommon EGFR Mutations
International Journal of Clinical Oncology（2021）
关键词
Afatinib,HER2 mutations,Lung cancer,Named patient use,NSCLC,Uncommon EGFR mutations
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要